ALKing the flames of lung cancer immunosensitivity

Immune checkpoint inhibitors (ICIs) are utilised in treating non‐small cell lung cancer (NSCLC) by enhancing the immune response against cancer cells. However, they are not effective against cancers with certain genetic alterations. A recent study by Mota et al. focussed on understanding why ALK+ NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Bayliss, Richard, Sarnowska, Elżbieta, Yeoh, Sharon, Sampson, Josephina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620113/
https://www.ncbi.nlm.nih.gov/pubmed/37795653
http://dx.doi.org/10.1002/1878-0261.13533
_version_ 1785130135003856896
author Bayliss, Richard
Sarnowska, Elżbieta
Yeoh, Sharon
Sampson, Josephina
author_facet Bayliss, Richard
Sarnowska, Elżbieta
Yeoh, Sharon
Sampson, Josephina
author_sort Bayliss, Richard
collection PubMed
description Immune checkpoint inhibitors (ICIs) are utilised in treating non‐small cell lung cancer (NSCLC) by enhancing the immune response against cancer cells. However, they are not effective against cancers with certain genetic alterations. A recent study by Mota et al. focussed on understanding why ALK+ NSCLC cancers are immune cold and making them more receptive to ICIs using a vaccine‐based approach. The study highlighted cell‐specific differences in the presentation of immunogenic peptides and the location of tumours as factors in the poor immune response. Vaccines based on ALK peptides improved immune response, and when combined with ICIs, this led to a striking improvement in survival in a mouse model of ALK+ NSCLC.
format Online
Article
Text
id pubmed-10620113
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106201132023-11-03 ALKing the flames of lung cancer immunosensitivity Bayliss, Richard Sarnowska, Elżbieta Yeoh, Sharon Sampson, Josephina Mol Oncol Commentary Immune checkpoint inhibitors (ICIs) are utilised in treating non‐small cell lung cancer (NSCLC) by enhancing the immune response against cancer cells. However, they are not effective against cancers with certain genetic alterations. A recent study by Mota et al. focussed on understanding why ALK+ NSCLC cancers are immune cold and making them more receptive to ICIs using a vaccine‐based approach. The study highlighted cell‐specific differences in the presentation of immunogenic peptides and the location of tumours as factors in the poor immune response. Vaccines based on ALK peptides improved immune response, and when combined with ICIs, this led to a striking improvement in survival in a mouse model of ALK+ NSCLC. John Wiley and Sons Inc. 2023-10-12 /pmc/articles/PMC10620113/ /pubmed/37795653 http://dx.doi.org/10.1002/1878-0261.13533 Text en © 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Bayliss, Richard
Sarnowska, Elżbieta
Yeoh, Sharon
Sampson, Josephina
ALKing the flames of lung cancer immunosensitivity
title ALKing the flames of lung cancer immunosensitivity
title_full ALKing the flames of lung cancer immunosensitivity
title_fullStr ALKing the flames of lung cancer immunosensitivity
title_full_unstemmed ALKing the flames of lung cancer immunosensitivity
title_short ALKing the flames of lung cancer immunosensitivity
title_sort alking the flames of lung cancer immunosensitivity
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620113/
https://www.ncbi.nlm.nih.gov/pubmed/37795653
http://dx.doi.org/10.1002/1878-0261.13533
work_keys_str_mv AT baylissrichard alkingtheflamesoflungcancerimmunosensitivity
AT sarnowskaelzbieta alkingtheflamesoflungcancerimmunosensitivity
AT yeohsharon alkingtheflamesoflungcancerimmunosensitivity
AT sampsonjosephina alkingtheflamesoflungcancerimmunosensitivity

Ejemplares similares